Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced results of the recently completed phase III clinical trial for its VeriStrat® test. Data confirms that the non-invasive, blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for second-line treatment of advanced non-small cell lung cancer: chemotherapy or the targeted drug erlotinib (Tarceva®).
Help employers find you! Check out all the jobs and post your resume.
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced results of the recently completed phase III clinical trial for its VeriStrat® test. Data confirms that the non-invasive, blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for second-line treatment of advanced non-small cell lung cancer: chemotherapy or the targeted drug erlotinib (Tarceva®).
Help employers find you! Check out all the jobs and post your resume.
